Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aethlon MedicalAEMD -1.62%19 3-Year EBITDA Growth Rate is 72.10% as of Jun. 2026, which is 163% above its 10-year median of 27.40. GuruFocus rates AEMD with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 689 Medical Devices & Instruments companies, Aethlon Medical ranks better than 94.34% on this metric.
During the past 3 years, the average EBITDA Per Share Growth Rate was 72.10% per year.
During the past 5 years, the average EBITDA Per Share Growth Rate was 51.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Aethlon Medical was 72.10% per year. The lowest was 7.90% per year. And the median was 27.40% per year.
Aethlon Medical (NAS:AEMD) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Aethlon Medical 3-Year EBITDA Growth Rate Related Terms
AEMD vs PFSA, LUDG, NUMD: 3-Year EBITDA Growth Rate Comparison
For the Medical Devices subindustry, Aethlon Medical's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aethlon Medical 3-Year EBITDA Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Aethlon Medical's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Aethlon Medical's 3-Year EBITDA Growth Rate falls into.
Aethlon Medical 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 72.10% mean?
Aethlon Medical (AEMD) has a 3-Year EBITDA Growth Rate of 72.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aethlon Medical and its competitors. This is 163% above median its historical median of 27.40. Over the past decade, Aethlon Medical's 3-Year EBITDA Growth Rate has ranged from 7.90 to 72.10. According to the industry distribution chart, Aethlon Medical ranks #39 out of 689 companies in the Medical Devices & Instruments industry, placing it in the top 5.7%.
Is Aethlon Medical's 3-Year EBITDA Growth Rate too high?
Aethlon Medical's current 3-Year EBITDA Growth Rate of 72.10% is 163% above median its 10-year median of 27.40. Over the past 10 years, this metric has ranged from a low of 7.90 to a high of 72.10. The Medical Devices & Instruments industry median 3-Year EBITDA Growth Rate is 7.70. Aethlon Medical's value of 72.10% is 836.4% above this industry median. Based on the distribution chart, Aethlon Medical ranks #39 out of 689 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Aethlon Medical has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Aethlon Medical's 3-Year EBITDA Growth Rate compare to PFSA and LUDG?
According to the Medical Devices & Instruments industry distribution chart, Aethlon Medical ranks #39 out of 689 companies for 3-Year EBITDA Growth Rate. This places Aethlon Medical in the top 6% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 7.70. Aethlon Medical's value of 72.10% is 836.4% above this benchmark. Historically, Aethlon Medical's own 3-Year EBITDA Growth Rate has ranged from 7.90 to 72.10 over the past decade. While the company's 10-year median is 27.40 vs. the industry median of 7.70, Aethlon Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Medical Devices & Instruments company?
The median 3-Year EBITDA Growth Rate among Medical Devices & Instruments companies is 7.70, based on 689 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aethlon Medical's current 3-Year EBITDA Growth Rate of 72.10% is 836.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Aethlon Medical and its competitors. For the Medical Devices & Instruments industry, the median 3-Year EBITDA Growth Rate is 7.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aethlon Medical's current 3-Year EBITDA Growth Rate is 72.10%, which is 163% above median its own 10-year median of 27.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aethlon Medical stock overvalued right now?
Aethlon Medical (AEMD) has a current 3-Year EBITDA Growth Rate of 72.10%. The current 3-Year EBITDA Growth Rate is 72.10%, which is 163% above median its 10-year median of 27.40 and 836.4% above the Medical Devices & Instruments industry median of 7.70. Aethlon Medical's overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Aethlon Medical (AEMD), the current 3-Year EBITDA Growth Rate is 72.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aethlon Medical Inc is a medical therapeutic company focused on developing the Hemopurifier (HP), a clinical-stage investigational immunotherapeutic device designed to address unmet needs in oncology, life-threatening infectious diseases, organ transplantation and other disease states in which extracellular vesicles (EVs) contribute to disease progression. The Hemopurifier utilizes a proprietary lectin-based technology to bind and remove enveloped viruses and EVs from biological fluids. EVs have been associated with immune suppression, metastasis, and resistance to therapy in cancer, as well as progression of severe infectious diseases. The Company operates as a single reportable segment.
19GF Score
Get the complete analysis for AEMD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AEMD has been successfully added to your 
